MCID: UTR042
MIFTS: 22

Uterus Leiomyosarcoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Uterus Leiomyosarcoma

MalaCards integrated aliases for Uterus Leiomyosarcoma:

Name: Uterus Leiomyosarcoma 12
Leiomyosarcoma of the Corpus Uteri 60
Leiomyosarcoma of Corpus Uteri 12
Leiomyosarcoma of Uterus 74

Classifications:



External Ids:

Disease Ontology 12 DOID:5289
NCIt 51 C6340
ICD10 via Orphanet 35 C54.2
UMLS via Orphanet 75 C0280631
Orphanet 60 ORPHA213625
UMLS 74 C0280631

Summaries for Uterus Leiomyosarcoma

Disease Ontology : 12 A uterine Corpus sarcoma and leiomyosarcoma and uterine Corpus smooth muscle neoplasm that is located in the smooth muscle of the uterus.

MalaCards based summary : Uterus Leiomyosarcoma, also known as leiomyosarcoma of the corpus uteri, is related to uterine corpus epithelioid leiomyosarcoma and leiomyosarcoma. An important gene associated with Uterus Leiomyosarcoma is MKI67 (Marker Of Proliferation Ki-67). The drugs Docetaxel and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include the smooth muscle of the uterus, uterus and smooth muscle.

Related Diseases for Uterus Leiomyosarcoma

Diseases related to Uterus Leiomyosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 uterine corpus epithelioid leiomyosarcoma 11.2
2 leiomyosarcoma 10.2

Symptoms & Phenotypes for Uterus Leiomyosarcoma

Drugs & Therapeutics for Uterus Leiomyosarcoma

Drugs for Uterus Leiomyosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Docetaxel Approved, Investigational Phase 3,Phase 2,Not Applicable 114977-28-5 148124
2
Gemcitabine Approved Phase 3,Phase 2,Not Applicable 95058-81-4 60750
3
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
4
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
5
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
6
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
7
Sargramostim Approved, Investigational Phase 3,Phase 2 123774-72-1, 83869-56-1
8
Bevacizumab Approved, Investigational Phase 3 216974-75-3
9
Histamine Approved, Investigational Phase 3 51-45-6 774
10
Cyproheptadine Approved Phase 3 129-03-3 2913
11
Doxil Approved June 1999 Phase 3,Phase 2 31703
12 Antineoplastic Agents, Alkylating Phase 3,Phase 2
13 Anti-Bacterial Agents Phase 3,Phase 2
14 Alkylating Agents Phase 3,Phase 2
15 Immunologic Factors Phase 3,Phase 2,Not Applicable
16 Antimetabolites Phase 3,Phase 2,Not Applicable
17 Anti-Infective Agents Phase 3,Phase 2,Not Applicable
18 Antimitotic Agents Phase 3,Phase 2,Not Applicable
19 Immunosuppressive Agents Phase 3,Phase 2,Not Applicable
20 Antimetabolites, Antineoplastic Phase 3,Phase 2,Not Applicable
21 Antiviral Agents Phase 3,Phase 2,Not Applicable
22 Angiogenesis Modulating Agents Phase 3,Phase 2
23 Angiogenesis Inhibitors Phase 3,Phase 2
24
Isophosphamide mustard Phase 3,Phase 2 0
25 Antibiotics, Antitubercular Phase 3,Phase 2
26 Topoisomerase Inhibitors Phase 3,Phase 2
27 Adjuvants, Immunologic Phase 3,Phase 2
28 Endothelial Growth Factors Phase 3,Phase 2
29 Antibodies, Monoclonal Phase 3,Phase 2
30 Mitogens Phase 3,Phase 2
31 Immunoglobulins Phase 3,Phase 2
32 Antibodies Phase 3,Phase 2
33 Antineoplastic Agents, Immunological Phase 3,Phase 2
34 Immunoglobulin G Phase 3
35 Histamine Antagonists Phase 3
36 Neurotransmitter Agents Phase 3
37 Gastrointestinal Agents Phase 3
38 Serotonin Agents Phase 3
39 Serotonin Antagonists Phase 3
40 Anti-Allergic Agents Phase 3
41 Antipruritics Phase 3
42 Dermatologic Agents Phase 3
43 Histamine H1 Antagonists Phase 3
44
Histamine Phosphate Phase 3 51-74-1 65513
45
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
46
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
47
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
48
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
49
nivolumab Approved Phase 2 946414-94-4
50
Ipilimumab Approved Phase 2 477202-00-9

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
2 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
4 Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Active, not recruiting NCT01533207 Phase 3 Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride
5 Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Terminated NCT01012297 Phase 3 Docetaxel;Gemcitabine Hydrochloride
6 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
7 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
8 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
9 Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma Unknown status NCT00033709 Phase 2 temozolomide;thalidomide
10 Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma Completed NCT02249702 Phase 2 gemcitabine + docetaxel;trabectedin
11 Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01637961 Phase 2 Alisertib
12 Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy Completed NCT01220609 Phase 2 Ixabepilone
13 Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00378911 Phase 2 sunitinib malate
14 Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma Completed NCT02428192 Phase 2
15 Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma Completed NCT00282087 Phase 2 gemcitabine, docetaxel, doxorubicin
16 Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus Completed NCT00379145 Phase 2 trabectedin
17 Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma Completed NCT00101127 Phase 2 docetaxel;gemcitabine hydrochloride
18 Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma Completed NCT00856050 Phase 2 letrozole
19 Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma Completed NCT02131480 Phase 2 Doxorubicin;Trabectedin
20 Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00025220 Phase 2 Thalidomide
21 Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00031629 Phase 2 Docetaxel;Gemcitabine Hydrochloride
22 Chemotherapy in Treating Patients With Sarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride
23 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
24 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
25 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
26 Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma Completed NCT00227669 Phase 2 docetaxel;gemcitabine hydrochloride
27 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
28 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
29 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
30 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
31 Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract Completed NCT00003334 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
32 Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma Completed NCT00004066 Phase 2 docetaxel;gemcitabine hydrochloride
33 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
34 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
35 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
36 Thalidomide in Treating Patients With Gynecologic Sarcomas Completed NCT00006005 Phase 2 thalidomide
37 FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study Recruiting NCT03926936 Phase 2 Fulvestrant
38 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Active, not recruiting NCT02601209 Phase 1, Phase 2 Pazopanib;Pazopanib Hydrochloride;Sapanisertib
39 Olaparib and Temozolomide in Treating Patients With Advanced, Metastatic, or Unresectable Uterine Leiomyosarcoma Not yet recruiting NCT03880019 Phase 2 Olaparib;Temozolomide
40 Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma Terminated NCT00414076 Phase 2 Letrozole
41 Gemcitabine in Treating Patients With Recurrent or Refractory Cancer of the Uterus Terminated NCT00003316 Phase 2 gemcitabine hydrochloride
42 Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus Terminated NCT00003054 Phase 2 paclitaxel
43 Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus Terminated NCT00033644 Phase 2 cisplatin;dacarbazine;doxorubicin hydrochloride;mitomycin C
44 Pazopanib for Treating Uterine Leiomyosarcoma Withdrawn NCT02378142 Phase 2 Pazopanib
45 Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery Unknown status NCT01958580 Not Applicable Gemcitabine Hydrochloride;Docetaxel
46 Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus Completed NCT00614835 Not Applicable Docetaxel plus Gemcitabine
47 Collecting Tumor Samples From Patients With Gynecological Tumors Completed NCT00897442
48 Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford Recruiting NCT01793168

Search NIH Clinical Center for Uterus Leiomyosarcoma

Genetic Tests for Uterus Leiomyosarcoma

Anatomical Context for Uterus Leiomyosarcoma

The Foundational Model of Anatomy Ontology organs/tissues related to Uterus Leiomyosarcoma:

20
The Smooth Muscle Of The Uterus

MalaCards organs/tissues related to Uterus Leiomyosarcoma:

42
Uterus, Smooth Muscle, Endothelial

Publications for Uterus Leiomyosarcoma

Articles related to Uterus Leiomyosarcoma:

# Title Authors Year
1
LEIOMYOSARCOMA OF THE CORPUS UTERI. ( 14326171 )
1965

Variations for Uterus Leiomyosarcoma

Expression for Uterus Leiomyosarcoma

Search GEO for disease gene expression data for Uterus Leiomyosarcoma.

Pathways for Uterus Leiomyosarcoma

GO Terms for Uterus Leiomyosarcoma

Sources for Uterus Leiomyosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....